ORDI Rare Disease Day Campaign Off and Running with Race for 7


In an effort to raise awareness about the rare disease community, ORDI is organizing the Race for 7 run.

In honor of Rare Disease Day (Feb. 28), Organization for Rare Disease India (ORDI) will be running wild.

In an effort to increase public knowledge about the rare disease community, empower those within it, and address unmet medical needs around the world, ORDI is organizing the Race for 7; an awareness run to highlight the challenges of being a rare disease patient or family member.

The Race for 7 will be taking place simultaneously at 3 different locations on Sunday, February 25, including: St. Joseph’s Indian High School in Bengaluru, Mumbai, and at Washington Monument National Park in Washington D.C. ORDI hopes to register 7,000 runners across the 3 locations, each of whom will run for 7 miles. The symbolic number “7,” of course, represents the estimated 7,000 rare diseases around the world.

ORDI was founded in 2014 by Dr Harsha Karur Rajasimha and his team, who stress the importance of participation in awareness events promoting the rare disease community: “The event is open to the public and diverse individuals — including patients with rare diseases – are encouraged to register at racefor7.com,” Dr Rajasimha said.

Rare diseases affect 1 out of every 20 Indians and, among these, 50% are children. Most rare disease patients in India die before their 5th birthday due to a lack of timely diagnosis and appropriate medical intervention.

Rare Disease Day was established in 2008 and was officially recognized in the United States for the first time in 2009. Since its initial observation, more than 94 countries have participated.

Additionally, for the second year in a row, ORDI will also be exhibiting at the National Institutes of Health Rare Disease Day event on March 1. For collaboration and partnership opportunities, contact the Racefor7USA team at usa[@]ordindia[.]org.

Related Videos
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease
Mercedes Martinez, MD: Treatment Strategies for Autoimmune Hepatitis
© 2024 MJH Life Sciences

All rights reserved.